IL292650B2 - COSTIMULATORY CHIMERIC ANTIGEN RECEPTOR T CELLS TARGETING IL13Ra2 - Google Patents

COSTIMULATORY CHIMERIC ANTIGEN RECEPTOR T CELLS TARGETING IL13Ra2

Info

Publication number
IL292650B2
IL292650B2 IL292650A IL29265022A IL292650B2 IL 292650 B2 IL292650 B2 IL 292650B2 IL 292650 A IL292650 A IL 292650A IL 29265022 A IL29265022 A IL 29265022A IL 292650 B2 IL292650 B2 IL 292650B2
Authority
IL
Israel
Prior art keywords
cells
domain
seq
antigen receptor
chimeric antigen
Prior art date
Application number
IL292650A
Other languages
English (en)
Hebrew (he)
Other versions
IL292650B1 (en
IL292650A (en
Original Assignee
Hope City
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55533940&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL292650(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hope City filed Critical Hope City
Publication of IL292650A publication Critical patent/IL292650A/en
Publication of IL292650B1 publication Critical patent/IL292650B1/en
Publication of IL292650B2 publication Critical patent/IL292650B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5437—IL-13
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A61K40/4211—CD19 or B4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4214—Receptors for cytokines
    • A61K40/4217—Receptors for interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70517—CD8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/7056—Lectin superfamily, e.g. CD23, CD72
    • C07K14/70564—Selectins, e.g. CD62
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/47—Brain; Nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70514—CD4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
IL292650A 2014-09-19 2015-09-18 COSTIMULATORY CHIMERIC ANTIGEN RECEPTOR T CELLS TARGETING IL13Ra2 IL292650B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462053068P 2014-09-19 2014-09-19
PCT/US2015/051089 WO2016044811A1 (en) 2014-09-19 2015-09-18 COSTIMULATORY CHIMERIC ANTIGEN RECEPTOR T CELLS TARGETING IL13Rα2

Publications (3)

Publication Number Publication Date
IL292650A IL292650A (en) 2022-07-01
IL292650B1 IL292650B1 (en) 2023-12-01
IL292650B2 true IL292650B2 (en) 2024-04-01

Family

ID=55533940

Family Applications (6)

Application Number Title Priority Date Filing Date
IL292650A IL292650B2 (en) 2014-09-19 2015-09-18 COSTIMULATORY CHIMERIC ANTIGEN RECEPTOR T CELLS TARGETING IL13Ra2
IL308324A IL308324A (en) 2014-09-19 2015-09-18 IL13RA2-targeted chimeric antigen receptor T cells
IL251188A IL251188B (en) 2014-09-19 2015-09-21 Central memory t cells for t cell stress therapy
IL251196A IL251196B (en) 2014-09-19 2017-03-15 Costimulatory chimeric antigen receptor t cells targeting il13ra2
IL280576A IL280576B (en) 2014-09-19 2021-02-02 Costimulatory chimeric antigen receptor t cells targeting il13ra2
IL292828A IL292828A (en) 2014-09-19 2022-05-08 Central memory t cells for adoptive t cell therapy

Family Applications After (5)

Application Number Title Priority Date Filing Date
IL308324A IL308324A (en) 2014-09-19 2015-09-18 IL13RA2-targeted chimeric antigen receptor T cells
IL251188A IL251188B (en) 2014-09-19 2015-09-21 Central memory t cells for t cell stress therapy
IL251196A IL251196B (en) 2014-09-19 2017-03-15 Costimulatory chimeric antigen receptor t cells targeting il13ra2
IL280576A IL280576B (en) 2014-09-19 2021-02-02 Costimulatory chimeric antigen receptor t cells targeting il13ra2
IL292828A IL292828A (en) 2014-09-19 2022-05-08 Central memory t cells for adoptive t cell therapy

Country Status (14)

Country Link
US (3) US9914909B2 (enExample)
EP (4) EP3587446A1 (enExample)
JP (7) JP6657195B2 (enExample)
KR (3) KR102683584B1 (enExample)
CN (3) CN107002084B (enExample)
AU (4) AU2015317351B2 (enExample)
BR (3) BR112017005631A2 (enExample)
CA (2) CA2961654A1 (enExample)
DK (1) DK3200591T3 (enExample)
ES (2) ES2738705T3 (enExample)
IL (6) IL292650B2 (enExample)
MX (4) MX387135B (enExample)
RU (2) RU2749922C2 (enExample)
WO (2) WO2016044811A1 (enExample)

Families Citing this family (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9738696B2 (en) 2012-08-09 2017-08-22 The Board Of Trustees Of The Leland Stanford Junior University Superkines and synthekines: repurposed cytokines with new and enhanced signaling activities
EP2934532B1 (en) 2012-12-20 2019-10-23 Purdue Research Foundation Chimeric antigen receptor-expressing t cells as anti-cancer therapeutics
US9657105B2 (en) 2013-03-15 2017-05-23 City Of Hope CD123-specific chimeric antigen receptor redirected T cells and methods of their use
ES2738705T3 (es) * 2014-09-19 2020-01-24 Hope City Linfocitos T de receptor de antígeno quimérico coestimulante que se dirigen a IL13R 2
PT3298033T (pt) 2015-05-18 2020-09-22 Tcr2 Therapeutics Inc Composições e utilizações médicas para reprogramação de tcr utilizando proteínas de fusão
HK1256130A1 (zh) 2015-07-21 2019-09-13 City Of Hope 用於嵌合抗原受体和其他受体的表达的t细胞
EP3575403A1 (en) * 2015-08-05 2019-12-04 Yoo Young Pharm Co., Ltd. Chimeric antigen receptor, and t cells in which chimeric antigen receptor is expressed
NZ746700A (en) * 2016-04-01 2023-04-28 Kite Pharma Inc Bcma binding molecules and methods of use thereof
PE20200400A1 (es) 2016-04-01 2020-02-26 Kite Pharma Inc Receptores quimericos y metodos de uso de los mismos
SG10201912489QA (en) 2016-04-01 2020-02-27 Kite Pharma Inc Chimeric antigen and t cell receptors and methods of use
MA44507A (fr) * 2016-04-01 2019-02-06 Amgen Inc Récepteurs chimères de flt3 et leurs procédés d'utilisation
JP7282521B2 (ja) 2016-04-08 2023-05-29 パーデュー・リサーチ・ファウンデイション Ｃａｒ ｔ細胞療法のための方法および組成物
WO2017192536A1 (en) 2016-05-02 2017-11-09 University Of Kansas Eliminating mhc restriction from the t cell receptor as a strategy for immunotherapy
KR102497013B1 (ko) * 2016-06-07 2023-02-20 맥스-델브뤼크-센트럼 퓌어 몰레쿨라레 메디친 Bcma에 결합하는 키메라 항원 수용체 및 car-t 세포
EP3468994A1 (en) * 2016-06-08 2019-04-17 Intrexon Corporation Cd33 specific chimeric antigen receptors
AU2017306432A1 (en) 2016-08-02 2019-03-21 TCR2 Therapeutics Inc. Compositions and methods for TCR reprogramming using fusion proteins
NZ751571A (en) * 2016-09-16 2025-10-31 Baylor College Medicine Platform for activation and expansion of virus-specific t-cells
CA3036745A1 (en) 2016-10-07 2018-04-12 TCR2 Therapeutics Inc. Compositions and methods for t-cell receptors reprogramming using fusion proteins
CA3044593A1 (en) 2016-11-22 2018-05-31 TCR2 Therapeutics Inc. Compositions and methods for tcr reprogramming using fusion proteins
WO2018102761A1 (en) 2016-12-02 2018-06-07 City Of Hope Methods for manufacturing and expanding t cells expressing chimeric antigen receptors and other receptors
US20200078401A1 (en) * 2016-12-07 2020-03-12 La Jolla Institute For Allergy And Immunology Compositions for cancer treatment and methods and uses for cancer treatment and prognosis
US12473343B2 (en) 2017-01-10 2025-11-18 The General Hospital Corporation Targeted t cells with cytotoxicity toward immunosuppressive cells
EP3579870A4 (en) 2017-02-07 2020-12-30 Seattle Children's Hospital (DBA Seattle Children's Research Institute) PHOSPHOLIPID ETHER (PLE) T CAR-LYMPHOCYTE TUMOR (CTCT) TARGETING AGENTS
CN108395481B (zh) * 2017-02-08 2021-02-05 西比曼生物科技（香港）有限公司 一种靶向cd20的car的构建及其工程化t细胞的活性鉴定
WO2018156711A1 (en) * 2017-02-22 2018-08-30 H. Lee Moffitt Cancer Center And Research Institute, Inc. Il13ra2-binding chimeric antigen receptors
JP7178355B2 (ja) 2017-02-28 2022-11-25 エンドサイト・インコーポレイテッド Ｃａｒ ｔ細胞療法のための組成物および方法
WO2018181207A1 (ja) * 2017-03-27 2018-10-04 ノイルイミューン・バイオテック株式会社 キメラ抗原受容体
AU2018251206A1 (en) 2017-04-14 2019-10-31 The General Hospital Corporation Chimeric antigen receptor T cells targeting the tumor microenvironment
CA3060443A1 (en) 2017-04-19 2018-10-25 Board Of Regents, The University Of Texas System Immune cells expressing engineered antigen receptors
CN107267555B (zh) * 2017-05-27 2020-03-20 上海优卡迪生物医药科技有限公司 一种基于octs技术的恶性胶质瘤car-t治疗载体及其构建方法和应用
US12364724B2 (en) * 2017-08-11 2025-07-22 City Of Hope Oncolytic virus expressing a car T cell target and uses thereof
EP3694558B1 (en) 2017-10-10 2024-04-10 Medicenna Therapeutics Inc. Il-4-fusion formulations for treatment of central nervous system (cns) tumors
CN111542545A (zh) * 2017-11-03 2020-08-14 索伦托治疗有限公司 Cd38定向嵌合抗原受体构建体
US20200345823A1 (en) * 2017-11-07 2020-11-05 Xiuli Wang Treatment of cns lymphoma and systemic lymphoma with intracerebroventricularly administered cd19 car
CN109971721B (zh) * 2017-12-28 2023-10-31 上海细胞治疗研究院 自表达cd47抗体的间皮素特异性car-t细胞及其用途
CN109971712B (zh) * 2017-12-28 2023-06-20 上海细胞治疗研究院 特异性靶向cd19抗原且高水平稳定表达pd-1抗体的car-t细胞及用途
CA3089319A1 (en) 2018-01-22 2019-07-25 Seattle Children's Hospital (dba Seattle Children's Research Institute) Methods of use for car t cells
WO2019148006A1 (en) * 2018-01-26 2019-08-01 City Of Hope Chimeric antigen receptors and methods for reducing off target toxicity
BR112020015884A2 (pt) * 2018-02-06 2020-12-08 Seattle Children's Hospital (dba Seattle Children's Research Institute) Receptores de antígeno quimérico (cars) específicos de fluoresceína exibindo a função de célula t ótima contra os tumores marcados por fl-ple
JP2021512635A (ja) * 2018-02-12 2021-05-20 ザ ジェネラル ホスピタル コーポレイション 腫瘍微小環境を標的とするキメラ抗原受容体
EP3755349A4 (en) 2018-02-21 2021-11-17 Board of Regents, The University of Texas System PROCESS FOR ACTIVATION AND EXPANSION OF NATURAL KILLER CELLS AND THEIR USES
US12240870B2 (en) 2018-02-23 2025-03-04 Purdue Research Foundation Sequencing method for CAR T cell therapy
CA3093791A1 (en) * 2018-03-14 2019-09-19 Seattle Children's Hospital (dba Seattle Children's Research Institute) Il-13 receptor alpha 2 targeted, zetakine directed t cell immunotherapy
SG11202008795SA (en) * 2018-03-14 2020-10-29 Seattle Childrens Hospital Dba Seattle Childrens Res Inst Il-13 receptor alpha 2 (il13ra2) chimeric antigen receptor for tumor specific t cell immunotherapy
US12090170B2 (en) 2018-04-06 2024-09-17 The Regents Of The University Of California Methods of treating glioblastomas
EP3773632A4 (en) 2018-04-06 2022-05-18 The Regents of The University of California Methods of treating egfrviii expressing glioblastomas
AU2019275479B2 (en) * 2018-05-21 2022-12-08 Biosceptre (Aust) Pty Ltd Chimeric antigen receptors with modified linker domains and uses thereof
US12404497B2 (en) 2018-06-01 2025-09-02 Medicenna Therapeutics Inc. Uses and methods for oncolytic virus targeting of IL-4/IL-13 and fusions thereof
CN112533943B (zh) * 2018-06-01 2024-03-05 利兰斯坦福初级大学董事会 Il-13/il-4超级因子：免疫细胞靶向性构建体及其使用方法
CN120988098A (zh) 2018-06-29 2025-11-21 希望之城公司 用于治疗某些自身免疫病症的cd6靶向性嵌合抗原受体
EP3834833A4 (en) * 2018-08-10 2022-05-18 Eutilex Co., Ltd. Cancer antigen-specific cytotoxic t cells
CN113423409A (zh) * 2018-11-06 2021-09-21 华盛顿大学 嵌合抗原受体记忆样(carml) nk细胞及其制备和使用方法
US20230065784A1 (en) 2019-03-21 2023-03-02 City Of Hope Composition and method for reducing expression of checkpoint inhibitors in t cells expressing a car or ctl
WO2020205751A1 (en) 2019-03-29 2020-10-08 City Of Hope Methods for manufacturing t cells expressing of chimeric antigen receptors and other receptors
WO2020243007A1 (en) * 2019-05-24 2020-12-03 City Of Hope Ccr4 targeted chimeric antigen receptor modified t cells for treatment of ccr4 positive malignancies
CN112204135A (zh) * 2019-07-06 2021-01-08 苏州克睿基因生物科技有限公司 一种表达cd3抗体受体复合物的免疫细胞及其用途
WO2021004400A1 (zh) * 2019-07-06 2021-01-14 苏州克睿基因生物科技有限公司 一种表达cd3抗体受体复合物的免疫细胞及其用途
MX2022000896A (es) * 2019-07-24 2022-02-14 Regeneron Pharma Receptores de antigenos quimericos con especificidad por mage-a4 y usos de los mismos.
EP3769816A1 (en) * 2019-07-25 2021-01-27 Ospedale Pediatrico Bambino Gesù Car-cd123 vector and uses thereof
WO2021138454A1 (en) 2019-12-30 2021-07-08 City Of Hope Methods of making and using regulatory t cells and effector t cells having chimeric antigen receptors targeted to cd6, cd19, and/or an il-13r for treatment of autoimmune disorders and cancers
EP4097127A2 (en) * 2020-01-31 2022-12-07 City of Hope TARGETED CHIMERIC ANTIGEN RECEPTOR MODIFIED T CELLS FOR TREATMENT OF IL13Ralpha2 POSITIVE MALIGNANCIES
WO2021183755A1 (en) * 2020-03-11 2021-09-16 City Of Hope Dual-targeting chimeric antigen receptor modified t cells comprising il-13 and chlorotoxin for cancer treatment
CN115515971A (zh) * 2020-03-12 2022-12-23 希望之城公司 治疗IL13Rα2阳性恶性病的靶向性嵌合抗原受体修饰的T细胞
US12365871B2 (en) 2020-04-28 2025-07-22 Lyell Immunopharma, Inc. Methods for culturing cells
CA3184784A1 (en) * 2020-05-27 2021-12-02 The Medical College Of Wisconsin, Inc. Improved lentiviral vector transfer plasmid and methods of use
GB202011993D0 (en) 2020-07-31 2020-09-16 Adc Therapeutics Sa ANTI-IL 13Ra2 antibodies
IL300470A (en) * 2020-08-11 2023-04-01 Yeda res & development co ltd Veto type CAR-T cells
JP2023541253A (ja) * 2020-09-10 2023-09-29 ムスタング バイオ，インコーポレイテッド 癌標的のｃａｒ－ｔ細胞を含む併用療法と、それを癌治療に使用する方法
WO2022098797A1 (en) * 2020-11-04 2022-05-12 Fred Hutchinson Cancer Research Center Therapeutic targeting of mesothelin in acute myeloid leukemia with chimeric antigen receptor t cell therapy
US20230364138A1 (en) 2020-11-23 2023-11-16 City Of Hope Engineered t cells for expression of chimeric anitgen receptors
JP2023553419A (ja) 2020-12-03 2023-12-21 センチュリー セラピューティクス，インコーポレイテッド 遺伝子操作細胞およびその使用
US11661459B2 (en) 2020-12-03 2023-05-30 Century Therapeutics, Inc. Artificial cell death polypeptide for chimeric antigen receptor and uses thereof
WO2022133169A1 (en) 2020-12-18 2022-06-23 Century Therapeutics, Inc. Chimeric antigen receptor systems with adaptable receptor specificity
CN114907485B (zh) * 2021-02-08 2024-04-26 浙江大学 一种以内源性蛋白质分子替代单结构域抗体的嵌合抗原受体
US12144827B2 (en) 2021-02-25 2024-11-19 Lyell Immunopharma, Inc. ROR1 targeting chimeric antigen receptor
US20240158521A1 (en) * 2021-03-18 2024-05-16 The Wistar Institute Of Anatomy And Biology DNA-ENCODED BISPECIFIC ANTIBODIES TARGETING IL13Ra2 AND METHODS OF USE IN CANCER THERAPEUTICS
WO2022212525A2 (en) 2021-03-30 2022-10-06 City Of Hope Car t cell therapy and ifn gamma
US20230190799A1 (en) * 2021-07-21 2023-06-22 City Of Hope Chimeric antigen receptor t cells targeting cea and anti-cea-il2 immunocytokines for cancer therapy
CN113621077B (zh) * 2021-09-02 2023-01-31 山东大学 一种tim-3/cd28融合蛋白及所述融合蛋白修饰的car-t细胞
EP4176895A1 (en) * 2021-11-08 2023-05-10 AvenCell Europe GmbH Targeting modules against il13ra2 or her2 for use in combination with a chimeric antigen receptor
WO2023130462A1 (zh) * 2022-01-10 2023-07-13 卡瑞济(北京)生命科技有限公司 靶向IL13Rα2的嵌合抗原受体及其用途
CN115960257B (zh) * 2022-09-29 2023-10-27 卡瑞济(北京)生命科技有限公司 靶向IL13Rα2的经优化的嵌合抗原受体及其用途
EP4588939A1 (en) 2024-01-16 2025-07-23 Universitat de Barcelona Interleukin-13 receptor subunit alpha-2 (il13ralpha2) targeting moieties for the treatment and prevention of il13ralpha2-positive cancer

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010025177A1 (en) * 2008-08-26 2010-03-04 City Of Hope Method and compositions for enhanced anti-tumor effector functioning of t cells

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2096749T3 (es) 1990-12-14 1997-03-16 Cell Genesys Inc Cadenas quimericas para vias de transduccion de señal asociada a un receptor.
US5712149A (en) 1995-02-03 1998-01-27 Cell Genesys, Inc. Chimeric receptor molecules for delivery of co-stimulatory signals
ATE297986T1 (de) * 1995-02-24 2005-07-15 Gen Hospital Corp Neuorientierung der zellulären immunität durch rezeptorchimären
GB9526131D0 (en) 1995-12-21 1996-02-21 Celltech Therapeutics Ltd Recombinant chimeric receptors
US6576232B1 (en) 1998-04-03 2003-06-10 The Penn State Research Foundation IL13 mutants
DE69924615T3 (de) 1998-07-30 2011-05-05 The Government Of The United States Of America, Represented By The Department Of Health & Human Services, National Institute Of Health, Office Of Technology Transfer Thymosin beta 4 stimuliert wundheilung
AU2472400A (en) 1998-10-20 2000-05-08 City Of Hope CD20-specific redirected T cells and their use in cellular immunotherapy of CD20+ malignancies
WO2001034645A2 (en) * 1999-11-11 2001-05-17 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Mutated il-13 molecules and their uses
US7560280B2 (en) 2000-11-03 2009-07-14 Kourion Therapeutics Gmbh Human cord blood derived unrestricted somatic stem cells (USSC)
US7070995B2 (en) 2001-04-11 2006-07-04 City Of Hope CE7-specific redirected immune cells
US20090257994A1 (en) * 2001-04-30 2009-10-15 City Of Hope Chimeric immunoreceptor useful in treating human cancers
US7514537B2 (en) * 2001-04-30 2009-04-07 City Of Hope Chimeric immunoreceptor useful in treating human gliomas
US11278594B2 (en) * 2001-04-30 2022-03-22 City Of Hope Chimeric immunoreceptor useful in treating human cancers
WO2002088334A1 (en) 2001-04-30 2002-11-07 City Of Hope Chimeric immunoreceptor useful in treating human cancers
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
US7446190B2 (en) 2002-05-28 2008-11-04 Sloan-Kettering Institute For Cancer Research Nucleic acids encoding chimeric T cell receptors
EP1501226B1 (en) 2003-07-24 2007-09-19 Matsushita Electric Industrial Co., Ltd. Method, encoder and communication device for encoding parallel concatenated data
US20050113564A1 (en) 2003-11-05 2005-05-26 St. Jude Children's Research Hospital Chimeric receptors with 4-1BB stimulatory signaling domain
US7754441B2 (en) * 2003-11-17 2010-07-13 Genentech, Inc. Compositions and methods for the treatment of tumor of hematopoietic origin
DE102004043271A1 (de) * 2004-09-07 2006-03-09 Linde Ag Verfahren zur Synthese von Zirkoniumcarboxylaten
HUE030210T2 (en) 2004-11-24 2017-04-28 Hutchinson Fred Cancer Res Methods for using IL-21 to identify adoptive immunotherapy and tumor antigens
DE602006017435D1 (de) * 2005-12-21 2010-11-18 Sentoclone Ab Verfahren zur expansion tumorreaktiver t-lymphozyten zur immuntherapie von patienten mit krebs
US20080293070A1 (en) * 2005-12-21 2008-11-27 Rafick-Pierre Sekaly Markers for Memory T Cells and Uses Thereof
EP2126054B1 (en) 2007-01-31 2016-07-06 Yeda Research And Development Company Limited Redirected, genetically-engineered t regulatory cells and their use in suppression of autoimmune and inflammatory disease
WO2009040562A1 (en) * 2007-09-26 2009-04-02 Ucb Pharma S.A. Dual specificity antibody fusions
BR112012017164A2 (pt) * 2009-12-22 2019-09-24 Novartis Ag proteína de fusão de região constante de anticorpo-cd47 tetravalente
GB2481983A (en) * 2010-07-12 2012-01-18 Hart Fenton & Co Ltd A ship including a gas tank room
US20130164272A1 (en) 2010-08-18 2013-06-27 Udai S. Kammula Methods of identifying central memory t cells and obtaining antigen-specific t cell populations
PH12013501201A1 (en) * 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
MX359513B (es) * 2011-03-23 2018-10-01 Hutchinson Fred Cancer Res Metodo y composiciones para inmunoterapia celular.
MX354359B (es) * 2011-03-29 2018-02-28 Roche Glycart Ag Variantes de fragmento cristalizable (fc) de los anticuerpos.
EP2532740A1 (en) 2011-06-11 2012-12-12 Michael Schmück Antigen-specific CD4+ and CD8+ central-memory T cell preparations for adoptive T cell therapy
US9447194B2 (en) * 2012-02-13 2016-09-20 Seattle Children's Hospital Bispecific chimeric antigen receptors and encoding polynucleotides thereof
MX380109B (es) * 2012-08-20 2025-03-12 Fred Hutchinson Cancer Center Star Metodo y composiciones para inmunoterapia celular.
US9657105B2 (en) * 2013-03-15 2017-05-23 City Of Hope CD123-specific chimeric antigen receptor redirected T cells and methods of their use
EP3626748A1 (en) * 2014-01-13 2020-03-25 Stephen J. Forman Chimeric antigen receptors (cars) having mutations in the fc spacer region and methods for their use
ES2738705T3 (es) * 2014-09-19 2020-01-24 Hope City Linfocitos T de receptor de antígeno quimérico coestimulante que se dirigen a IL13R 2

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010025177A1 (en) * 2008-08-26 2010-03-04 City Of Hope Method and compositions for enhanced anti-tumor effector functioning of t cells

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
MAHESH JONNALAGADDA ET AL,, CHIMERIC ANTIGEN RECEPTORS (CARS) INCORPORATING MUTATIONS IN THE IGG4 FC SPACER REGION TO ELIMINATE FC RECEPTOR RECOGNITION RESULTS IN IMPROVED CAR T CELL PERSISTENCE AND ANTI-TUMOR EFFICACY, 7 November 2013 (2013-11-07) *
S. KONG ET AL,, SUPPRESSION OF HUMAN GLIOMA XENOGRAFTS WITH SECOND-GENERATION IL13R-SPECIFIC CHIMERIC ANTIGEN RECEPTOR-MODIFIED T CELLS, 1 November 2012 (2012-11-01) *

Also Published As

Publication number Publication date
KR102683584B1 (ko) 2024-07-10
CA2961676A1 (en) 2016-03-24
JP7216045B2 (ja) 2023-01-31
NZ730208A (en) 2024-03-22
ES2876235T3 (es) 2021-11-12
US10676717B2 (en) 2020-06-09
JP2020156494A (ja) 2020-10-01
JP6986190B2 (ja) 2021-12-22
MX2017003557A (es) 2017-10-12
RU2017111300A (ru) 2018-10-19
RU2017111298A (ru) 2018-10-19
BR122024000360A2 (pt) 2024-02-27
EP3200591B1 (en) 2021-03-31
KR20170057351A (ko) 2017-05-24
CN113789336A (zh) 2021-12-14
JP2023014100A (ja) 2023-01-26
EP3200591B2 (en) 2024-09-25
MX2021012720A (es) 2022-01-06
IL292650B1 (en) 2023-12-01
AU2024201326A1 (en) 2024-04-11
MX2017003596A (es) 2017-10-20
EP3916084A1 (en) 2021-12-01
WO2016044853A1 (en) 2016-03-24
KR20230169455A (ko) 2023-12-15
CN113637640A (zh) 2021-11-12
CN107002084A (zh) 2017-08-01
IL251188B (en) 2022-07-01
IL292650A (en) 2022-07-01
JP6657195B2 (ja) 2020-03-04
JP2017534262A (ja) 2017-11-24
EP3194433A1 (en) 2017-07-26
AU2020203651A1 (en) 2020-06-25
US9914909B2 (en) 2018-03-13
CN107404881A (zh) 2017-11-28
IL280576B (en) 2022-06-01
MX387135B (es) 2025-03-18
IL280576A (en) 2021-03-25
JP2023052506A (ja) 2023-04-11
KR102610715B1 (ko) 2023-12-08
JP6711819B2 (ja) 2020-06-17
US20200318069A1 (en) 2020-10-08
RU2017111300A3 (enExample) 2019-09-04
JP2017529081A (ja) 2017-10-05
MX2021006400A (es) 2021-07-15
RU2749922C2 (ru) 2021-06-21
US20160340649A1 (en) 2016-11-24
EP3200591A4 (en) 2018-04-04
RU2017111298A3 (enExample) 2019-03-13
KR20170054509A (ko) 2017-05-17
JP2020100626A (ja) 2020-07-02
EP3194433B1 (en) 2019-05-22
IL308324A (en) 2024-01-01
CN107404881B (zh) 2021-07-09
BR112017005630B1 (pt) 2023-12-12
JP7171871B2 (ja) 2022-11-15
DK3200591T3 (da) 2021-06-21
BR112017005630A2 (pt) 2018-06-26
MX383042B (es) 2025-03-13
AU2015317351A1 (en) 2017-04-06
JP2022017333A (ja) 2022-01-25
ES2738705T3 (es) 2020-01-24
AU2015317351B2 (en) 2020-07-02
HK1247046A1 (zh) 2018-09-21
EP3200591A1 (en) 2017-08-09
EP3587446A1 (en) 2020-01-01
AU2021277651A1 (en) 2021-12-23
BR112017005631A2 (pt) 2018-06-26
WO2016044811A1 (en) 2016-03-24
WO2016044853A8 (en) 2017-04-06
IL292828A (en) 2022-07-01
IL251196A0 (en) 2017-05-29
RU2763523C2 (ru) 2021-12-30
IL251196B (en) 2021-02-28
CA2961654A1 (en) 2016-03-24
CN107002084B (zh) 2021-09-10
ES2876235T5 (en) 2025-02-12
IL251188A0 (en) 2017-05-29
US20180265844A1 (en) 2018-09-20

Similar Documents

Publication Publication Date Title
IL292650B2 (en) COSTIMULATORY CHIMERIC ANTIGEN RECEPTOR T CELLS TARGETING IL13Ra2
JP2017522862A5 (enExample)
IL259120A (en) Her2-targeted antigen chimeric receptors2
JP2017537627A5 (enExample)
JP2016514457A5 (enExample)
JP2018520679A5 (enExample)
JP2018029594A5 (enExample)
WO2018098365A3 (en) Compositions and methods for tcr reprogramming using fusion proteins
JP2016538855A5 (enExample)
FI3824905T3 (fi) Menetelmä ja koostumuksia soluimmunoterapiaa varten
JP2017515464A5 (enExample)
JP2017538401A5 (enExample)
JP2020512284A5 (enExample)
JP2015525065A5 (enExample)
JP2016534717A5 (enExample)
JP2016520074A5 (enExample)
NZ725079A (en) Transgene genetic tags and methods of use
NZ722076A (en) Chimeric antigen receptor containing a toll-like receptor intracellular domain
JP2016508725A5 (enExample)
JP2015509717A5 (enExample)
EP4286522A3 (en) Fusion proteins of pd-1 and 4-1bb
JP7389741B2 (ja) Ｔ細胞受容体または人工ｔ細胞受容体を発現するためのｒｎａレプリコン
RU2018140056A (ru) Композиции и способы с использованием т-клеток с химерным рецептором аллоантигена
UA115235C2 (uk) Ген токсину axmi335 bacillus thuringiensis та спосіб його застосування
MY173686A (en) Fc gamma receptor iib variants